Neuralocity
- Company typePrivate
- Founded2016
- HeadquartersChandler, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Neuralocity firmographics
Firmographics- Name
- Neuralocity
- Legal name
- Neuralocity LLC
- Website
- https://neuralocity.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Neuralocity industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Neuralocity is headquartered
LocationHeadquarters
- HQ city
- Chandler
- HQ country
- United States
- HQ region
- North America
Markets served
Neuralocity business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations
Neuralocity product offering
Product offeringCore offering
Neuralocity is a deep technology company that develops artificial intelligence applied to experimental drug discovery. Its offer spans machine learning, software consulting, predictive analytics, and data visualization services, targeting challenges in pharmaceutical and biotech R&D. The firm currently operates in stealth mode and has not publicly disclosed named products, pricing, or customer engagements.
Product overview
Neuralocity is a deep technology company operating in stealth mode, working at the intersection of artificial intelligence and experimental drug discovery. The company has not publicly disclosed specific products, modules, or named offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- Artificial Intelligence for Experimental Drug Discovery Application of artificial intelligence to challenges in experimental drug discovery, intended for pharmaceutical and biotechnology R&D organizations.
- Machine Learning Consulting Software consulting services involving machine learning development and deployment for clients in scientific and research domains.
- Predictive Analytics Services Development and delivery of predictive analytics capabilities for clients working with experimental and scientific datasets.
- Data Visualization Services Data visualization services that translate experimental and analytical outputs into visual formats for research and business stakeholders.
Companies that use Neuralocity
Customer profileIdeal customer profiles1 record
Neuralocity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Neuralocity partnerships and signals
Strategic signalRecent moves3 records
Neuralocity competitors and assessment
Company assessmentDirect peers
- XtalPi: XtalPi combines AI, quantum physics, and large-scale experimental data for drug discovery and materials science. It is a direct peer in applying AI to experimental drug discovery workflows and partnering with major pharma on discovery programs.
- Exscientia: Exscientia builds AI-designed drug candidates with end-to-end discovery capabilities and has publicly disclosed pharma partnerships. It is a direct competitor in the AI-driven experimental drug discovery space, with a comparable end-customer profile of large pharmaceutical companies.
- Insitro: Insitro applies machine learning to predictive modeling in drug discovery, combining ML with high-throughput experimental biology. It is a direct peer because both companies position themselves at the intersection of AI and experimental drug discovery, the same target customer base (large pharma partners), and a comparable platform strategy.
- Atomwise: Atomwise applies AI to small-molecule drug discovery, partnering with pharma and academic groups. It is a direct peer in target identification and hit generation through AI, comparable to Neuralocity's experimental drug discovery focus.
- Recursion Pharmaceuticals: Recursion uses AI and high-throughput experimental biology to discover new therapeutics, with a public pipeline and large pharma partnerships. It directly competes with Neuralocity in the AI-for-experimental-drug-discovery category and serves the same large-pharma partner customer base.
- BenevolentAI: BenevolentAI applies machine learning to drug discovery across multiple therapeutic areas. It is a direct peer in AI-augmented experimental drug discovery, with a comparable model of operating a centralized AI platform that targets pharma collaborations.
Broad incumbents
- Isomorphic Labs: Isomorphic Labs is Alphabet's drug-discovery AI subsidiary, applying deep learning to molecular design and partnering with pharma majors (Novartis, Lilly). It is a broad incumbent peer with significantly more capital and compute, competing for the same AI-drug-discovery partnership value pool.
- Schrödinger: Schrödinger provides physics-based computational chemistry and AI-augmented drug-design software used across pharma R&D. It is a broad incumbent peer that overlaps with Neuralocity on the AI/computational side of drug discovery, though its core platform is more established and commercially deployed.
Emerging players
- Owkin: Owkin applies AI/ML to biomedical research and drug discovery, with a particular emphasis on multi-modal data integration. It is an emerging player with meaningful overlap to Neuralocity on AI applied to pharma and life-sciences R&D, although its portfolio spans diagnostics and clinical research as well.
- Iambic: Iambic (formerly Entasis-backed) builds AI-driven platforms for small-molecule drug discovery with experimental validation. It is an emerging player with direct overlap to Neuralocity's AI-for-experimental-drug-discovery positioning and serves the same pharma-partner customer profile.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Neuralocity social profiles
Digital presenceNeuralocity financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neuralocity leadership team
Management profileNumber of profiles
Profiles2 records
Neuralocity funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neuralocity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neuralocity
What does Neuralocity do?
Neuralocity is a deep technology company that develops artificial intelligence applied to experimental drug discovery. Its offer spans machine learning, software consulting, predictive analytics, and data visualization services, targeting challenges in pharmaceutical and biotech R&D. The firm currently operates in stealth mode and has not publicly disclosed named products, pricing, or customer engagements.
Is Neuralocity a public or private company?
Neuralocity is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Neuralocity founded?
Neuralocity was founded in 2016. It employs 1 to 10 people.
Where is Neuralocity based?
Neuralocity is headquartered in Chandler, United States, in the North America region.
Who are Neuralocity's main competitors?
Direct peers on record are XtalPi, Exscientia, Insitro, Atomwise, Recursion Pharmaceuticals and BenevolentAI. Broad incumbents are Isomorphic Labs and Schrödinger. Emerging players are Owkin and Iambic.
Does Neuralocity have an API?
No public API is recorded for Neuralocity.
What industry is Neuralocity in?
Neuralocity's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 7372.